{"url_path":"/sec/fulc/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 Exhibits.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-04-27","source_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-178814-index.html","accession_number":"0001193125-26-178814","cik":"0001680581","ticker":"FULC","issuer_name":"Fulcrum Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1680581/0001193125-26-178814-index.html","primary_entity_key":"0001680581","primary_entity_name":"Fulcrum Therapeutics, Inc."},"word_count":331,"has_tables":true,"body_markdown":"Item 6. Exhibits.\n\n \n\nExhibit\n\nNumber\n\n \n\nDescription\n\n  3.1\n\n \n\n[Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2019).](https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004324/a2239321zex-3_1.htm)\n\n  3.2\n\n \n\n[Certificate of Amendment of the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2023).](https://www.sec.gov/Archives/edgar/data/1680581/000119312523164435/d463131dex31.htm)\n\n  3.3\n\n \n\n[Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on July 22, 2019).](https://www.sec.gov/Archives/edgar/data/0001680581/000104746919004324/a2239321zex-3_2.htm)\n\n  31.1*\n\n[Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](fulc-ex31_1.htm)\n\n  31.2*\n\n \n\n[Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](fulc-ex31_2.htm)\n\n  32.1+\n\n[Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](fulc-ex32_1.htm)\n\n  32.2+\n\n \n\n[Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](fulc-ex32_2.htm)\n\n101.INS\n\nInline XBRL Instance Document\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).\n\n \n\n* Filed herewith.\n\n+ Furnished herewith.\n\n67\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nFULCRUM THERAPEUTICS, INC.\n\nDate: April 27, 2026\n\nBy:\n\n/s/ Alex C. Sapir\n\nAlex C. Sapir\n\nPresident and Chief Executive Officer (Principal Executive Officer)\n\n \n\nDate: April 27, 2026\n\n \n\nBy:\n\n/s/ Alan Musso\n\n \n\n \n\n \n\nAlan Musso\n\n \n\n \n\n \n\nChief Financial Officer (Principal Financial Officer)\n\n \n\n \n\n \n\n \n\n \n\n68"}